RxDoctor Payments Data

Ronald Sarrazine, MD

Internal Medicine · Fort Wayne, INNPI 1538146709

Payments from drug & device makers

$8,442in general payments, 2019–2025

Across 593 payments — averaging $14.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Pfizer$1K
  • AstraZeneca$988
  • Lilly USA, LLC$675
  • Axsome Therapeutics, Inc.$457
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$8,433100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,442 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$83,547
Medicare patients
227
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$97,484
JardianceEmpagliflozin49$76,913
EliquisApixaban44$71,794
MounjaroTirzepatide29$53,053
TrulicityDulaglutide24$50,803
RybelsusSemaglutide27$35,861
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$34,130
FarxigaDapagliflozin Propanediol26$26,461
XareltoRivaroxaban20$24,980
JanuviaSitagliptin Phosphate20$24,573
ProliaDenosumab13$23,204
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$15,134
Breo ElliptaFluticasone/Vilanterol31$14,691
VascepaIcosapent Ethyl18$13,215
Tresiba Flextouch U-200Insulin Degludec14$12,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,248$133,34492 claims
Lilly USA, LLCMounjaro, Trulicity$675$103,85753 claims
Boehringer IngelheimJardiance$42$76,91349 claims
PfizerEliquis$1,031$71,79444 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$294$63,95581 claims
AstraZenecaFarxiga, Symbicort$988$32,86038 claims
Johnson & JohnsonXarelto$14$24,98020 claims
MerckJanuvia$195$24,57320 claims
AmgenProlia$308$23,20413 claims
AbbVieSynthroid$1,240$4,27872 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$3,138361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →